高山教授と友成先生が共著者を務めた原著論文がHepatol Resに掲載されました。
Hatanaka T, Shimose S, Ito T, Tani J, Tomonari T, Saeki I, Takeuchi Y, Sasaki K, Honma Y, Sasaki R, Yoshioka N, Naito T, Takeuchi M, Yasunaka T, Sakata M, Iwamoto H, Itano S, Kanayama Y, Shirono T, Tanabe N, Yamamoto T, Naganuma A, Nishina S, Otsuka M, Kobara H, Takami T, Takayama T, Kawaguchi T, Kawashima H, Harada M, Miyaaki H, Kakizaki S; Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group.
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.
Hepatol Res. 2025 Aug 21.
doi: 10.1111/hepr.70023. Online ahead of print. PMID: 40838970
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.
Hepatol Res. 2025 Aug 21.
doi: 10.1111/hepr.70023. Online ahead of print. PMID: 40838970
三井先生による総説がMedical Science Digestに掲載されました。
三井康裕, 岡本耕一, 佐藤康史, 高山哲治.
大腸がんに対する薬物療法の進歩.
Medical Science Digest. 2025 Sep; 51(10): 13-16